Delivery Order SPE2DE24D0013-SPE2D625F0PBP
- Not listed
- The U.S. Defense Department's Medical Supply Chain organization awarded a $2,835 firm fixed-price delivery order to Cepheid Inc. on August 29, 2025, for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The delivery order, which extends through September 8, 2025, will be performed at Cepheid's facility in Sunnyvale, California. This award carries no small business set-aside designation and represents a continuation of...
- The U.S. Defense Department's Medical Supply Chain awarded Cepheid Inc., a Sunnyvale, California-based molecular diagnostics manufacturer, a firm fixed-price delivery order valued at $20,400 on August 11, 2025, with an ultimate completion date of August 18, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, involves diagnostic testing solutions for COVID-19, influenza, and respiratory syncytial virus (RSV)—infectious diseases commonly detected through Cepheid's GeneXpert molecular...
- The Defense Department's Medical Supply Chain awarded a $4,080 firm fixed-price delivery order to Cepheid Inc. on July 18, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, designated as XPCOV2/FLU/RSV-10, represents a delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. Work will be performed at Cepheid's facility in Sunnyvale, California. This award reflects...
- The U.S. Defense Department's Medical Supply Chain agency awarded a $3,400 firm fixed-price delivery order to Cepheid Inc. on July 14, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, which is due for completion by July 21, 2025, utilizes no set-aside designation and will be performed at Cepheid's facility in Sunnyvale, California. This delivery order represents a continuation of Cepheid's established role as...
- The U.S. Defense Logistics Agency, through its Medical Supply Chain division, awarded Cepheid Inc. a delivery order valued at $22,240 on September 9, 2025, for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV). This firm fixed-price delivery order, which has no set-aside designation, is scheduled for completion by September 16, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. Cepheid is a for-profit...
- The U.S. Defense Department's Medical Supply Chain awarded a $8,640 firm fixed-price delivery order to Cepheid Inc., a molecular diagnostics manufacturer based in Sunnyvale, California, on September 9, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, is for diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection, with performance completion targeted for September 16, 2025. The contract contains no set-aside designation and represents a...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $6,468.30 to Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions. This firm fixed-price delivery order, issued on August 11, 2025, with an ultimate completion date of August 18, 2025, covers diagnostic testing solutions for COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The award carries no set-aside designation and represents a task order under...
- The U.S. Defense Logistics Agency awarded a $29,478.60 firm fixed-price delivery order to Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, on August 6, 2025, with an ultimate completion date of August 13, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, procures diagnostic testing solutions for COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The contract carries no set-aside designation and represents a relatively modest...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a $20,400 firm fixed-price delivery order to Cepheid Inc. on July 10, 2025, with an ultimate completion date of July 17, 2025. The contract, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic solutions for detecting COVID-19, influenza, and respiratory syncytial virus (RSV). Cepheid, a Sunnyvale, California-based manufacturer specializing in advanced diagnostic systems, will perform the work at its...
- The U.S. Defense Logistics Agency, operating under the Medical Supply Chain function, awarded a $20.4K firm fixed-price delivery order to Cepheid Inc. on September 18, 2025, with a completion date of September 25, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic solutions for COVID-19, influenza, and respiratory syncytial virus (RSV) testing, with performance to be executed at Cepheid's facility in Sunnyvale, California. This award carries no set-aside...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D625F0PBPDelivery Order
The U.S. Defense Department's Medical Supply Chain awarded an $8,160 firm fixed-price delivery order to Cepheid Inc. on August 8, 2025, for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The delivery order, which carries an ultimate completion date of August 15, 2025, will be performed in Sunnyvale, California, where Cepheid maintains its headquarters. This award represents no set-aside designation and reflects the contractor's ongoing role as a primary supplier of advanced diagnostic systems and reagent kits to federal healthcare entities. Cepheid, a for-profit manufacturer specializing in molecular diagnostic technologies, has established itself as a key federal contractor through multiple vehicle contracts with the Department of Veterans Affairs and Defense Logistics Agency. This delivery order likely derives from one of the company's two significant Indefinite Delivery/Indefinite Quantity (IDIQ) contracts with the VA, including a $32.8 million single-award IDIQ with Veterans Integrated Service Network 6 for molecular diagnostic testing reagents and assays through September 30, 2030. Cepheid's expertise in infectious disease diagnostics, combined with its existing federal infrastructure, positions it to rapidly deliver the required diagnostic capabilities supporting defense and veteran healthcare missions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.2k | 8/8/25 |